Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Singleron Raises $30 Million for Gexscope® Single-Cell Analysis Technology

publication date: Sep 15, 2020

Singleron Biotechnologies, a Nanjing-Suzhou start-up developing its Gexscope® high-throughput single-cell multiplex analysis technology, completed a $30 million Series A round led by Lilly Asia Ventures. Founded in 2018, Singleron applies its single cell analysis technologies to clinical diagnosis, drug development and health management. Singleron will use the proceeds to develop its single-cell platform products and their clinical applications, to accelerate commercialization of its technologies and to build an international presence. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020